West Nile virus (WNV) infections are typically asymptomatic. Less than 1% present with meningitis, encephalitis, myelitis, or acute flaccid paralysis, collectively coined West Nile neuroinvasive disease (WNND).
workup for underlying inflammatory, neoplastic, or metabolic processes were unremarkable.
Symptoms progressed, resulting in a flaccid left leg and new proximal right leg weakness. Repeat EMG-NCS on hospital day 16 localized the lesion to the lumbosacral nerve roots and/or anterior horn cells (figure, F). At this point CSF testing for WNV was still pending. Although supportive care is the mainstay of therapy, a benefit of high-dose steroids in WNND has been reported. 3 Given the progressive weakness with electrodiagnostic evidence of ongoing axon loss, he was started on empiric IV methylprednisolone. Nerve root biopsy was considered but never pursued given that WNV antibody testing was still pending. WNV immunoglobulin M in CSF returned positive on hospital day 24 and steroids were discontinued. There was no change in the patient's examination after steroids, and he developed no other sequelae of WNND. At follow-up 8 weeks later his examination was unchanged.
Discussion. While WNND was an initial differential diagnosis, we pursued an extensive workup to evaluate for other infectious, inflammatory, and neoplastic etiologies.
Prior analysis of CSF in 250 patients with WNND documented a mean CSF protein of 101 mg/dL (range 32-295 mg/dL) in those with encephalitis, levels higher than those in patients with only meningitis. 4 Although the same study reports an incremental increase in CSF protein on repeat examination in 33% of patients, the exact figures are not published. CSF protein in poliomyelitis peaks around 2-3 weeks into the paralytic stage of the illness before eventually normalizing. While a similar temporal pattern was observed, the absolute amount of CSF protein was substantially higher in our case. 5 Repeat CSF analysis 8 days after the first showed a protein of 1,011 mg/dL, a value much higher than previously reported in WNND and other infectious motor neuronopathies such as poliomyelitis. This finding forced us to revisit our differential. The interim progression of weakness and considerable delay in WNV serology prompted a trial of steroids in this clinical quagmire, albeit with great hesitation. CSF serology returned positive 23 days after it was sent, confirming the diagnosis of WNND. In retrospect, this patient was the first case of WNND in Missouri during the 2012 outbreak.
In conclusion, this case demonstrates that a markedly elevated CSF protein (in excess of 1 g/dL) can be observed in the setting of WNND. It also emphasizes how delays in critical test results can result in additional, sometimes unnecessary, diagnostic and therapeutic endeavors. Soon after this case, our institution switched the laboratory used for WNV testing, resulting in a drop in turnaround time from 2-3 weeks to 48-72 hours for CSF and serum antibody results. Author contributions: Dr. Maiti contributed to the collection and interpretation of the data, the writing of the manuscript, and the preparation of the figure. Dr. Bucelli contributed to the collection and interpretation of the data, the writing of the manuscript, and the preparation of the figure. He also provided feedback and guidance to Dr. Maiti during the preparation of the manuscript. 
